The Cancer Letter

Inside information on cancer research and drug development

Drugs & Targets

MPDL3280A receives second breakthrough therapy designation

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

FDA granted a second breakthrough designation to the immunotherapy MPDL3280A (anti-PDL1).

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Guest Editorial

An elephant in the room: Grief in young adults with cancer

Young adults with cancer are starting to break the silence about grief. Most people think of grief following the death of a loved one, but grief can accompany any event that disrupts or challenges our sense of normalcy or ourselves. During this first week of December, National Grief Awareness Week, we can raise awareness about grief in young adults with cancer to help ensure that no one grieves alone. xxx:more
By Casey Walsh
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account